{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:45:20Z","timestamp":1791477920086,"version":"4.3.4"},"reference-count":106,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This paper reviews the features of pediatric essential thrombocythemia (ET). ET is a rare disease in children, challenging pediatric and adult hematologists alike. The current WHO classification acknowledges classical Philadelphia-negative MPNs and defines diagnostic criteria, mainly encompassing adult cases. The presence of one of three driver mutations (JAK2V617F, CALR, and MPL mutations) represent the proof of clonality typical of ET. Pediatric ET cases are thus usually confronted by adult approaches. These can fit only some patients, because only 25\u201340% of cases present one of the driver mutations. The diagnosis of hereditary, familial thrombocytosis and the exclusion of reactive\/secondary thrombocytosis must be part of the diagnostic process in children and can clarify most of the negative cases. Still, many children present a clinical, histological picture of ET, with a molecular triple wild-type status. Moreover, prognosis seems more benign, at least within the first few decades of follow-up. Thrombotic events are rare, and only minor hemorrhages are ordinarily observed. As per the management, the need to control symptoms must be balanced with the collateral effects of lifelong drug therapy. We conclude that these differences concert a compelling case for a very careful therapeutic approach and advocate for the importance of further cooperative studies.<\/jats:p>","DOI":"10.3390\/cancers13236147","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T02:48:13Z","timestamp":1638845293000},"page":"6147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Essential Thrombocythemia in Children and Adolescents"],"prefix":"10.3390","volume":"13","author":[{"given":"Maria Caterina","family":"Putti","sequence":"first","affiliation":[{"name":"Clinic of Pediatric Hematology-Oncology, Department of Women\u2019s and Children\u2019s Health, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-9596","authenticated-orcid":false,"given":"Irene","family":"Bertozzi","sequence":"additional","affiliation":[{"name":"First Medical Clinic, Department of Medicine\u2014DIMED, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-1864","authenticated-orcid":false,"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[{"name":"First Medical Clinic, Department of Medicine\u2014DIMED, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc1708485","article-title":"Myeloproliferative neoplasms","volume":"377","author":"Barbui","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1046\/j.1365-2141.2000.02239-7.x","article-title":"Incidence of essential trombocytemia in children","volume":"110","author":"Hasle","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05329.x","article-title":"Primary and secondary thrombocytosis in childhood","volume":"129","author":"Dame","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000076520","article-title":"Age-dependent changes in the incidence and etiology of childhood thrombocytosis","volume":"111","author":"Matsubara","year":"2004","journal-title":"Acta Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12308-015-0256-1","article-title":"Myeloproliferative neoplasms in children","volume":"8","author":"Hofmann","year":"2015","journal-title":"J. Hematop."},{"key":"ref_9","unstructured":"Orkin, S., David, G., Nathan, D.G., and Nathan, D. (2008). Nathan and Oski\u2019s Hematology of Infancy and Childhood, Saunders."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Biino, G., Santimone, I., Minelli, C., Sorice, R., Frongia, B., Traglia, M., Ulivi, S., Di Castelnuovo, A., G\u00f6gele, M., and Nutile, T. (2013). Age-and sex-related variations in platelet count in Italy: A proposal of reference ranges based on 40987 subjects\u2019 data. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054289"},{"key":"ref_11","unstructured":"(2021, December 02). AIEOP Raccomandazioni per la Gestione Delle Trombocitosi in et\u00e0 Pediatrica. Available online: https:\/\/www.aieop.org\/web\/operatori-sanitari\/linee-guida-consensum\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"British Committee for standards in haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2007-06-094276","article-title":"The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","article-title":"Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative","volume":"108","author":"Randi","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/bjh.13329","article-title":"Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort","volume":"169","author":"Randi","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome","volume":"119","author":"Giona","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjh.12530","article-title":"Paediatric essential thrombocythaemia: Clinical and molecular features, diagnosis and treatment","volume":"163","author":"Fu","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3324\/haematol.2013.092684","article-title":"Primary thrombocytosis in children","volume":"99","author":"Kucine","year":"2014","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2010.08500.x","article-title":"Advances in understanding of the pathogenesis of familial thrombocythemia","volume":"152","author":"Teofili","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2141.1999.01710.x","article-title":"Hereditary thrombocythemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene","volume":"107","author":"Ghilardi","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocytosis","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2009.005918","article-title":"Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia","volume":"94","author":"Liu","year":"2009","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V89.1.101","article-title":"Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization","volume":"89","author":"Sungarian","year":"1997","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12959-016-0095-z","article-title":"Thrombopoietina and its receptor in normal and neoplastic hematopoiesis","volume":"14","author":"Kaushansky","year":"2016","journal-title":"Thromb. J."},{"key":"ref_26","first-page":"612","article-title":"Hepatic thrombopoietin mRNAis increased in acute infections","volume":"116","author":"Wolber","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-9343(94)90306-9","article-title":"Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis","volume":"97","author":"Tefferi","year":"1994","journal-title":"Am. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/10799900050023915","article-title":"Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B","volume":"20","author":"Wolber","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1651-2227.2001.tb00448.x","article-title":"Reactive thrombocytosis in children with upper urinary tract infections","volume":"90","author":"Garoufi","year":"2001","journal-title":"Acta Paediatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/09537100802233107","article-title":"Incidence and clinical significance of reactive thrombocytosis in children aged 1 to 24 months, hospitalized for community-acquired infections","volume":"19","author":"Indolfi","year":"2008","journal-title":"Platelets"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pedneo.2011.06.004","article-title":"Associations of reactive thrombocytosis with clinical characteristics in pediatric diseases","volume":"52","author":"Wang","year":"2011","journal-title":"Pediatr. Neonatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5045\/br.2018.53.3.233","article-title":"A cross-sectional retrospective study to analyze the underlying causes and clinical characteristics of children with reactive thrombocytosis at a Korean tertiary medical center","volume":"53","author":"Shin","year":"2018","journal-title":"Blood Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1111\/jth.15103","article-title":"Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients","volume":"18","author":"Thom","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_34","unstructured":"Rokkam, V.R., and Kotagiri, R. (2021). Secondary Thrombocytosis, StatPearls Publishing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00277-021-04485-0","article-title":"Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management","volume":"100","author":"Stockklausner","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0009922806289621","article-title":"Extreme thrombocytosis predicts Kawasaki disease in infants","volume":"45","author":"Nigrovic","year":"2006","journal-title":"Clin. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1542\/peds.2010-2576","article-title":"Diagnosis and prevention of iron deficiency and iron deficiency anemia in infants and young children (0\u20132 years of age)","volume":"126","author":"Baker","year":"2010","journal-title":"Pediatrics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.23682","article-title":"Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin","volume":"89","author":"Evstatiev","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kulnigg-Dabsch, S., Evstatiev, R., Dejaco, C., and Gasche, C. (2012). Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034520"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2257.1999.00226.x","article-title":"Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant","volume":"2","author":"Cerutti","year":"1999","journal-title":"Clin. Lab. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"536062","DOI":"10.1155\/2011\/536062","article-title":"Thrombocytosis: Diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies","volume":"2011","author":"Bleeker","year":"2011","journal-title":"Thrombosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00431-019-03424-6","article-title":"Emergency or urgent splenectomy in children for non-traumatic reasons","volume":"178","author":"Samuk","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3324\/haematol.2018.200832","article-title":"Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: A systematic review","volume":"104","author":"Ianotto","year":"2019","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-020-00571-8","article-title":"Myeloproliferative neoplasms in children, adolescents, and young adults","volume":"15","author":"Kucine","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Cancer Genome Project","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"52","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"80","author":"Zhao","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/jclinpath-2018-205227","article-title":"Essential thrombocythaemia with mutation in MPL: Clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes","volume":"71","author":"Arenillas","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2012.12","article-title":"How to manage children and young adults with myeloproliferative neoplasms","volume":"26","author":"Barbui","year":"2012","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1002\/pbc.24500","article-title":"MPL W515L mutation in pediatric essential thrombocythemia","volume":"60","author":"Farruggia","year":"2013","journal-title":"Pediatric Blood Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/leu.2015.167","article-title":"Distinct molecular abnormalities underlie unique clinical features essential thrombocythemia in children","volume":"30","author":"Fu","year":"2016","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e28183","DOI":"10.1002\/pbc.28183","article-title":"Essential thrombocythemia A retrospective case series","volume":"67","author":"Barg","year":"2020","journal-title":"Pediatric Blood Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2017-01-761767","article-title":"Bone marrow histology for the diagnosis of essential thrombocythemia in children: A multicenter Italian study","volume":"129","author":"Putti","year":"2017","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/leu.2015.205","article-title":"Mutational profile of childhood myeloproliferative neoplasms","volume":"29","author":"Karow","year":"2015","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.3324\/haematol.2016.142935","article-title":"Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation","volume":"101","author":"Kucine","year":"2016","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","article-title":"Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature","volume":"5","author":"Alimam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/08880018.2012.662712","article-title":"Spontaneous resolution of extreme thrombocytosis in 2 children","volume":"29","author":"Aviner","year":"2012","journal-title":"Pediatric Hematol. Oncol."},{"key":"ref_74","unstructured":"Hoffman, R., Benz, E.J., Shattil, S.J., Furie, B., Silberstein, L.E., McGlave, P., and Heslop, H. (2009). Essential thrombocythemia. Hematology: Basic Principles and Practice, Churchill Livingstone. [5th ed.]."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL negative classic myeloproliferative neoplasms: Consensus statements from the European Leukemia Net (ELN) and International Working Group-Myeloproliferative neoplasms research and treatment","volume":"25","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1002\/ajh.26137","article-title":"Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/09537104.2015.1041900","article-title":"Essential thrombocythemia with Mpl W515 K mutation in a child presenting with Budd-Chiari syndrome","volume":"26","author":"Tokgoz","year":"2015","journal-title":"Platelets"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MPH.0000000000000453","article-title":"JAK2+ Essential thrombocythemia in a young girl with Budd-Chiari syndrome: Diagnostic and therapeutic considerations when adult disease strikes the young","volume":"38","author":"Wigton","year":"2016","journal-title":"J. Pediatric Hematol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17474086.2019.1602034","article-title":"Contemporary management of essential thrombocythemia in children","volume":"12","author":"Randi","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.23635","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia","volume":"89","author":"Randi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in Polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Pereira","year":"2016","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3026(21)00204-0","article-title":"Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: A consensus-based proposal from the European Leukemia Net","volume":"8","author":"Harrison","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Daams","year":"2021","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"Valeriani","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: Treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr. phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"United Kingdom medical research council primary thrombocythemia 1 study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_92","unstructured":"Jinna, S., and Khandhar, P.B. (2021). Hydroxyurea Toxicity, StatPearls Publishing."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ajh.26286","article-title":"Real-life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study","volume":"96","author":"Voskaridou","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Manshouri","year":"2013","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","article-title":"Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)","volume":"6","author":"Masarova","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","article-title":"Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","volume":"28","author":"Pizzi","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.leukres.2011.06.030","article-title":"Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia","volume":"35","author":"Gugliotta","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ejh.13454","article-title":"Anagrelide in essential thrombocythemia (ET): Results from 150 patients over 25 years by the \u201cPh1-negative myeloproliferative neoplasms latium group\u201d","volume":"105","author":"Mazzucconi","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A children\u2019s oncology group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatric Blood Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"bcr2017220377","DOI":"10.1136\/bcr-2017-220377","article-title":"Ruxolitinib treatment in an infant with JAK2+ polycythemia vera-associated Budd-Chiari syndrome","volume":"2017","author":"Coskun","year":"2017","journal-title":"BMJ Case Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:08Z","timestamp":1760168528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":106,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13236147"],"URL":"https:\/\/doi.org\/10.3390\/cancers13236147","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}